Free Trial
NASDAQ:EGRX

Eagle Pharmaceuticals (EGRX) Stock Price, News & Analysis

Eagle Pharmaceuticals logo
$3.00 +0.11 (+3.63%)
As of 09:30 AM Eastern

About Eagle Pharmaceuticals Stock (NASDAQ:EGRX)

Key Stats

Today's Range
$2.36
$3.00
50-Day Range
$1.50
$2.90
52-Week Range
$1.50
$3.00
Volume
620 shs
Average Volume
8,193 shs
Market Capitalization
$38.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Eagle Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
45th Percentile Overall Score

EGRX MarketRank™: 

Eagle Pharmaceuticals scored higher than 45% of companies evaluated by MarketBeat, and ranked 653rd out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Eagle Pharmaceuticals.

    • Percentage of Shares Shorted

      0.46% of the float of Eagle Pharmaceuticals has been sold short.
    • Short Interest Ratio / Days to Cover

      Eagle Pharmaceuticals has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
    • Change versus previous month

    • Dividend Yield

      Eagle Pharmaceuticals does not currently pay a dividend.

    • Dividend Growth

      Eagle Pharmaceuticals does not have a long track record of dividend growth.

    • Percentage of Shares Shorted

      0.46% of the float of Eagle Pharmaceuticals has been sold short.
    • Short Interest Ratio / Days to Cover

      Eagle Pharmaceuticals has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.
    • Change versus previous month

    • News Coverage This Week

      MarketBeat has tracked 1 news article for Eagle Pharmaceuticals this week, compared to 0 articles on an average week.
    • Insider Buying vs. Insider Selling

      In the past three months, Eagle Pharmaceuticals insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      28.90% of the stock of Eagle Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

    • Percentage Held by Institutions

      85.36% of the stock of Eagle Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

    • Read more about Eagle Pharmaceuticals' insider trading history.
    Receive EGRX Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Eagle Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

    EGRX Stock News Headlines

    EGRX Eagle Pharmaceuticals, Inc. - Seeking Alpha
    I was wrong about Trump
    I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
    Eagle Pharmaceuticals to Delist from Nasdaq
    See More Headlines

    EGRX Stock Analysis - Frequently Asked Questions

    Eagle Pharmaceuticals' stock was trading at $0.50 at the beginning of 2025. Since then, EGRX stock has increased by 500.0% and is now trading at $3.00.
    View the best growth stocks for 2025 here
    .

    Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) issued its earnings results on Tuesday, November, 9th. The specialty pharmaceutical company reported $0.56 EPS for the quarter, beating analysts' consensus estimates of ($0.44) by $1.00. The specialty pharmaceutical company earned $39.85 million during the quarter, compared to analysts' expectations of $46.70 million.

    Shares of EGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Eagle Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Netflix (NFLX), Exxon Mobil (XOM), Advanced Micro Devices (AMD) and JPMorgan Chase & Co. (JPM).

    Company Calendar

    Last Earnings
    11/09/2021
    Today
    7/03/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    Pharmaceutical preparations
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:EGRX
    Fax
    N/A
    Employees
    100
    Year Founded
    2007

    Profitability

    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Pretax Margin
    N/A

    Debt

    Sales & Book Value

    Annual Sales
    $257.55 million
    Cash Flow
    $7.50 per share
    Price / Cash Flow
    0.40
    Price / Book
    N/A

    Miscellaneous

    Free Float
    9,234,000
    Market Cap
    $38.96 million
    Optionable
    No Data
    Beta
    0.83

    Social Links

    7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

    Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

    Get This Free Report

    This page (NASDAQ:EGRX) was last updated on 7/3/2025 by MarketBeat.com Staff
    From Our Partners